Atanis Biotech
Atanis Biotech develops the FAST-PASE® test, a fast and safe allergy testing solution designed to eliminate the risks associated with traditional methods like food challenges and invasive skin tests.
Classification
Profile
Funding
Funding details not yet available.
Provides fast, safe, and risk-free allergy testing, eliminating the uncertainty and fear associated with traditional food challenges and invasive skin tests.
Patients seeking allergy diagnostics and researchers in the allergy science field, endorsed by patients and trusted by researchers.
Per-Assay Fees - variable pricing based on sample volume, assay complexity, and turnaround time · Subscription / Retainer Models - fixed-monthly fees for a set number of assays plus priority support · Licensing of FAST-PASE® Platform - technology transfer to large diagnostic manufacturers (up-front royalty + milestone payments)
Direct Sales Force - specialized scientific account managers targeting pharma R&D heads and CRO procurement teams (Europe & North America) · Strategic Partnerships - collaborations with large CRO networks (e.g., IQVIA, Charles River) to embed FAST-PASE® into their service portfoli · Industry Conferences & Trade Shows - Allergy & Immunology (EAACI),
Strategic partnership with FARE (Food Allergy Research & Education) to enhance credibility and reach.
R&D, regulatory compliance, manufacturing
Proprietary FAST-PASE® technology, validated performance data, and a reputation as a leader in allergy science and diagnostics.
Developing and validating safe allergy testing methods, ensuring patient-centered performance, and maintaining leadership in allergy diagnostics.
Consultative / High-Touch - dedicated project managers guide clients through assay design, data interpretation, and regulatory filing · Long-Term Service Contracts - multi-year agreements for recurring safety-assessment pipelines, ensuring predictable revenue · Community Building - annual user symposium and a private online forum for scientists to
Competes with traditional invasive skin tests and food challenges by offering a safer, faster alternative that removes the gamble and uncertainty from allergy diagnosis.
Addresses the fear, uncertainty, and risks associated with traditional allergy testing methods, including invasive procedures and unreliable results.
- Expand Digital Lead Generation - Deploy targeted LinkedIn Sponsored Content and webinars focused on “Reducing Allergy-Related Trial Attri
- Value Propositions ↔ Customer Segments - The functional, non-invasive nature of FAST-PASE® directly addresses pharma’s need to de-risk al
- Strong Academic Roots - Spin-off from University of Bern with founders holding >70 years combined experience, lending scientific credibil
Team details not yet available.
No investors recorded yet.